Can meaningful activities slow dementia's toll? new study explores tailored plans.
NCT ID NCT05159869
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study involved 61 people with early-stage dementia and their caregivers. Researchers worked with participants to create a personalized plan of meaningful activities, designed to adapt as the disease progresses. The goal was to see if this approach could improve thinking skills and reduce difficult behavioral symptoms. The study focused on designing the program with direct input from people living with dementia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
61 people
The number who actually took part.
- Started
-
Jan 2022
- Finished
-
Jun 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Persons with dementia must: * Be English-speaking * Have a diagnosis of early-stage dementia based on standard assessments and diagnostic criteria \[e.g., Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5)\] * Be medically stable and responsive to the environment (e.g., not comatose). If participants with dementia are on any of four classes of psychotropic medications (antidepressant, benzodiazepines, antipsychotic, or anti-convulsant) or an anti-dementia medication (memantine or a cholinesterase inhibitor), the investigators will require that participants have been on a stable dose for 60 days prior to enrollment (typical time frame in clinical trials) to minimize possible confounding effects of concomitant medications. Exclusion Criteria: * Dementia in the moderate or severe stages * Bed-boundedness, defined as confined to bed or chair for at least 22 hours a day for at least four of the previous seven days * Are receiving palliative care or are at end-of-life * A diagnosis of schizophrenia or a bipolar disorder * Dementia secondary to probable head trauma * The participant is taking any neuroleptic medications or has any of the following medical diagnosis: (a) restless legs syndrome, (b) delirium, or (c) akathisia, medication-induced, or other movement disorders such as Parkinson's disease or essential tremor.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dementia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins School of Nursing
Baltimore, Maryland, 21205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can group wellness classes improve life after brain injury or dementia?
- Can a short talk with your doctor lower dementia risk?
- Can VR help people with dementia master daily tasks?
- A simple gel meets the Mouth's microscopic zoo
- Can a Phone-Based sleep program help dementia caregivers rest better?
- Can a video chat keep dementia care true to Patients' wishes?